Sodium‐glucose co‐transporter‐2 inhibitors and all‐cause mortality: A meta‐analysis of randomized controlled trials

This review of 21 RCTs (n=70,364) found that treatment with SGLT2 inhibitors was associated with a significant reduction in all‐cause mortality (OR [95% CI] 0.86 [0.81, 0.91] P < 0.00001) vs comparator and placebo.

Source:

Diabetes, Obesity and Metabolism